Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

KKaryopharm Therapeutics Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
K

Karyopharm Therapeutics Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
Loading financials
Income statement waterfall. Revenue $33.43M. Net result −$67.02M. A thin axis line marks the loss-zone boundary.

Income statement waterfall. Green diagonal stripes add to the running result, red diagonal stripes subtract from it, and a thin axis line marks the loss-zone boundary.

  • Revenue: $33.43M. Running result $33.43M. License And Other: $2.66M. Product: $30.78M.
  • Cost of revenue: $0. Running result $33.43M.
  • Gross profit: $33.43M. Running result $33.43M.
  • Research and development: −$28.96M. Running result $4.48M.
  • Selling, general and administrative: −$25.92M. Running result −$21.44M.
  • Other operating costs: −$1.09M. Running result −$22.53M.
  • Operating income: −$22.53M. Running result −$22.53M.
  • Other expense: −$44.5M. Running result −$67.02M.
  • Pre-tax loss: −$67.02M. Running result −$67.02M.
  • Income tax benefit: $0. Running result −$67.02M.
  • Net loss: −$67.02M. Running result −$67.02M.